Martin Stockler
NHMRC Clinical Trials Centre, University of Sydney, NSW, Australia
- This delegate is presenting an abstract at this event.
Martin Stockler is co-director of Oncology at the NHMRC Clinical Trials Centre and its Clinical Lead for ANZUP. He is Professor of Oncology and Clinical Epidemiology, University of Sydney, and consultant medical oncologist at the Concord Cancer Centre and Chris O’Brien Lifehouse RPA. His research has focused on improving survival and quality of life for people with cancer, particularly of the prostate, testis, kidney and breast. Special interests include: the design, execution, analysis and synthesis of cancer clinical trials; quality of life and preferences as outcome measures in clinical trials; evidence-based medicine in clinical practice and medical education; patient–doctor communication; and, the management of genitourinary, breast and advanced cancers.
Presentations this author is a contributor to:
Discussing and prescribing expensive unfunded anticancer drugs in Australia (#319)
3:00 PM
Deme J Karikios
Posters 2
A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours: The P3BEP Trial (ANZUP 1302) (#266)
3:00 PM
Howard Chan
Posters1
Randomised phase 3 trial of enzalutamide in first line androgen deprivation therapy for metastatic prostate cancer: the ANZUP ENZAMET Trial (ANZUP 1304) (#269)
3:00 PM
Ian Davis
Posters1
Baseline predictors of early treatment failure in patients with Platinum Resistant/ Refractory (PRR) and Potentially Platinum Sensitive (PPS) recurrent ovarian cancer (ROC) receiving ≥3 lines of chemotherapy- The Gynaecologic Cancer Intergroup (GCIG) Symptom Benefit Study (SBS) (#203)
3:00 PM
Peey-Sei Kok
Posters1
Randomised phase 3 double-blind placebo-controlled trial of methoxyflurane with periprostatic local anaesthesia to reduce the discomfort of transrectal ultrasound-guided prostate biopsy (Pain-Free TRUS B): ANZUP 1501 (#270)
3:00 PM
Ian Davis
Posters1
Is it time to change the primary endpoint in clinical trials in recurrent ovarian cancer (ROC)? Symptom burden and outcomes in patients with platinum resistant/refractory (PRR) and potentially platinum sensitive ROC receiving ≥3 lines of chemotherapy (PPS) – The Gynecologic Cancer Intergroup (GCIG) Symptom Benefit Study (SBS). (#167)
3:20 PM
Peey-Sei Kok
Best of the Best Posters - Survivorship & Supportive care
Randomised phase 3 trial of the addition of Mitomycin to BCG as adjuvant intravesical therapy for high-risk, non-muscle-invasive bladder cancer(ANZUP 1301) (#267)
3:00 PM
Howard Chan
Posters1
What Type of Evidence - Alternative trial designs for rare cancers (#93)
2:15 PM
Martin Stockler
The evidence base for rare cancers